Alder BioPharma (ALDR) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Alder BioPharma (ALDR) Misses Q2 EPS by 6c
August 5, 2015 4:02 PM EDT
BOTHELL, Wash., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the second quarter ended June 30, 2015.
"We believe that ALD403 has the potential to transform migraine prevention and represents a very significant market opportunity due to its outstanding efficacy demonstrated in our proof-of-concept trial, delivering approximately one third of patients to 100% reduction in their migraines in any given month," said... More
